Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Circulation

• Publication date

  2009-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.108.838672PMID 19273718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• thin filament regulation contraction and relaxation as a result of alterations in Invited Review: Pathophysiology of cardiac muscle

  2013cited by this paper
• Sarcomeric dysfunction in heart failure.

  2008cited by this paper
• Cardiac Myosin-binding protein C modulates the tuning of the molecular motor in the heart.

  2008cited by this paper
• Determination of protein structures--a series of fortunate events.

  2008cited by this paper
• Multiple Forms of Cardiac Myosin-binding Protein C Exist and Can Regulate Thick Filament Stability

  2007cited by this paper
• Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype.

  2007cited by this paper
• PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo.

  2007cited by this paper
• Control of In Vivo Contraction/Relaxation Kinetics by Myosin Binding Protein C: Protein Kinase A Phosphorylation–Dependent and –Independent Regulation

  2007cited by this paper
• Cardiac Myosin-Binding Protein C Is Required for Complete Relaxation in Intact Myocytes

  2007cited by this paper
• PKCε Increases Phosphorylation of the Cardiac Myosin Binding Protein C at Serine 302 both in Vitro and in Vivo

  2007cited by this paper
• Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure.

  2007cited by this paper
• Dilated and Hypertrophic Cardiomyopathy Mutations in Troponin and &agr;-Tropomyosin Have Opposing Effects on the Calcium Affinity of Cardiac Thin Filaments

  2007cited by this paper
• Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure.

  2007cited by this paper
• Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies

  2007cited by this paper
• Genetic Basis of Hypertrophic Cardiomyopathy: From Bench to the Clinics

  2007cited by this paper
• Differential Roles of Cardiac Myosin-Binding Protein C and Cardiac Troponin I in the Myofibrillar Force Responses to Protein Kinase A Phosphorylation

  2007cited by this paper
• Augmented Protein Kinase C-α–Induced Myofilament Protein Phosphorylation Contributes to Myofilament Dysfunction in Experimental Congestive Heart Failure

  2007cited by this paper
• Computational simulation of hypertrophic cardiomyopathy mutations in troponin I: influence of increased myofilament calcium sensitivity on isometric force, ATPase and [Ca2+]i.

  2007cited by this paper
• Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience

  2007cited by this paper
• Cardiac myosin-binding protein C in the heart.

  2007cited by this paper
• Ablation of Cardiac Myosin-Binding Protein-C Accelerates Stretch Activation in Murine Skinned Myocardium

  2006cited by this paper
• Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts — Evidence for novel phosphorylation sites

  2006cited by this paper
• Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice.

  2006cited by this paper
• Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants.

  2005cited by this paper
• Cardiomyocyte Stiffness in Diastolic Heart Failure

  2005cited by this paper
• Nonsense-mediated mRNA decay in mammals

  2005cited by this paper
• Cardiac Myosin-Binding Protein-C Phosphorylation and Cardiac Function

  2005cited by this paper
• Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice.

  2004cited by this paper
• Cardiac Myosin Binding Protein C: Its Role in Physiology and Disease

  2004cited by this paper
• Hypertrophic cardiomyopathy: an important global disease.

  2004cited by this paper
• Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy

  2003cited by this paper
• The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands.

  2003cited by this paper
• Effect of extraction of myosin binding protein C on contractility of rat heart.

  2003cited by this paper
• Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins.

  2003cited by this paper
• American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G

  2003cited by this paper
• Hypertrophic Cardiomyopathy in Cardiac Myosin Binding Protein-C Knockout Mice

  2002cited by this paper
• Phosphorylation of Troponin I by Protein Kinase A Accelerates Relaxation and Crossbridge Cycle Kinetics in Mouse Ventricular Muscle

  2001cited by this paper
• The molecular genetic basis for hypertrophic cardiomyopathy.

  2001cited by this paper
• A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance.

  2000cited by this paper
• Molecular Genetic Basis of Hypertrophic Cardiomyopathy:

  1998cited by this paper
• Cardiac myosin-binding protein C (MyBP-C): identification of protein kinase A and protein kinase C phosphorylation sites.

  1998cited by this paper
• Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy.

  1997cited by this paper
• Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein.

  1997cited by this paper
• Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation.

  1996cited by this paper
• Phosphorylation switches specific for the cardiac isoform of myosin binding protein‐C: a modulator of cardiac contraction?

  1995cited by this paper
• Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation.

  1995cited by this paper
• Determination of left ventricular mass by echocardiography in a normal population: effect of age and sex in addition to body size.

  1994cited by this paper
• The Clinical Perspective

  1994cited by this paper
• Alterations in Ca2+ sensitive tension due to partial extraction of C- protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers

  1991cited by this paper
• Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts.

  1988cited by this paper
• Phosphorylation of purified cardiac muscle C-protein by purified cAMP-dependent and endogenous Ca2+-calmodulin-dependent protein kinases.

  1984cited by this paper
• Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy

  1979cited by this paper

• Investigation of 25bp deletion-associated frameshift mutation in cardiac myosin-binding protein C gene and potential cardiomyopathy risks among Indian athletes

  2026cites this paper
• Cardiomyocyte hypertrophy co-localizes with accumulation of hyaluronan in cMyBPC+/- mice hearts

  2026cites this paper
• Cardiac myosin-binding protein C: potential early biomarker of myocardial injury in coronary artery bypass surgery

  2026cites this paper
• Myosin-binding protein H-like nonsense variants exhibit impaired sarcomere incorporation and alter contractility.

  2026cites this paper
• Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriers

  2025cites this paper
• A new hypothesis to explain disease dominance.

  2025cites this paper
• The Future of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Gene Therapy in Cardiomyopathies: A Review of Its Therapeutic Potential and Emerging Applications

  2025cites this paper
• Experimental Models of Hypertrophic Cardiomyopathy

  2025cites this paper
• Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy

  2025cites this paper
• Molecular mechanisms of altered contraction with the β-myosin R403Q mutation in porcine ventricular muscle and a human stem cell-derived cardiomyocyte model.

  2025cites this paper
• Precision Medicine in Cardiomyopathy: Advances and Future Directions

  2025cites this paper
• Tailored therapeutics for cardiomyopathies

  2025cites this paper
• The L348P point mutation in cardiac myosin binding protein-C alters transient responses to stretch, slows cardiac relaxation, and is embryonic lethal in homozygous CRISPR gene-edited mice.

  2025cites this paper
• cMyBP-C in hypertrophic cardiomyopathy: gene therapy and small-molecule innovations

  2025cites this paper
• AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models

  2025cites this paper
• Perinatal death in pig models of hypertrophic cardiomyopathy carrying sarcomere pathogenic variants

  2025cites this paper
• MYBPC3-c.772G > a mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.

  2024cites this paper
• MYBPHL nonsense mutations have poor sarcomere binding, are degraded, and cause abnormal contraction

  2024cites this paper
• Phenotypic Spectrum of Subclinical Sarcomere-Related Hypertrophic Cardiomyopathy and Transition to Overt Disease

  2024cites this paper
• Arg92Leu-cTnT Alters the cTnC-cTnI Interface Disrupting PKA-Mediated Relaxation

  2024cites this paper
• Genetic Basis of Hypertrophic Cardiomyopathy in Cats

  2024cites this paper
• Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

  2024cites this paper
• Mechanoresponsive regulation of myogenesis by the force-sensing transcriptional regulator Tono.

  2024cites this paper
• The W792R HCM missense mutation in the C6 domain of cardiac myosin binding protein-C increases contractility in neonatal mouse myocardium.

  2024cites this paper
• Exploring the Connection Between Relaxed Myosin States and the Anrep Effect

  2024cites this paper
• Hypertrophic cardiomyopathy in MYBPC3 carriers in aging

  2024cites this paper
• The Novel Frameshift Variant of the MYBPC3 Gene Associated with Hypertrophic Cardiomyopathy Significantly Decreases the Level of This Gene Transcript in the Myocardium

  2024cites this paper
• Evolving Strategies for Management of Obstructive Hypertrophic Cardiomyopathy.

  2024cites this paper
• Mechanoresponsive regulation of myogenesis by the force-sensing transcriptional regulator Tono.

  2024cites this paper
• Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy

  2024cites this paper
• Metabolic remodeling and calcium handling abnormality in induced pluripotent stem cell-derived cardiomyocytes in dilated phase of hypertrophic cardiomyopathy with MYBPC3 frameshift mutation

  2024influential citation
• From amoeboid myosin to unique targeted medicines for a genetic cardiac disease

  2024cites this paper
• Recreational and Occupational Physical Activity and Risk of Adverse Events in Truncating MYBPC3 Founder Variant Carriers

  2024cites this paper
• Is haploinsufficiency a sufficient mechanism for MYBPC3 truncating mutations?

  2023cites this paper
• An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy

  2023cites this paper
• The HCM – Linked Mutation Arg92Leu in TNNT2 Allosterically Alters the cTnC – cTnI Interface and Disrupts the PKA-mediated Regulation of Myofilament Relaxation

  2023cites this paper
• Physical activity impacts resting skeletal muscle myosin conformation and lowers its ATP consumption

  2023cites this paper
• A mechanically regulated liquid-liquid phase separation of the transcriptional regulator Tono instructs muscle development

  2023cites this paper
• Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities

  2023cites this paper
• Miocardiopatía hipertrófica, anomalía coronaria, enfermedad aterosclerótica y arritmia ventricular coexistiendo en un mismo paciente

  2023cites this paper
• Etiology of genetic muscle disorders induced by mutations in fast and slow skeletal MyBP-C paralogs

  2023cites this paper
• cMyBP-C ablation in human engineered cardiac tissue causes progressive Ca2+-handling abnormalities

  2023cites this paper
• Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM

  2023cites this paper
• Nonsense mediated decay factor UPF3B is associated with cMyBP-C haploinsufficiency in hypertrophic cardiomyopathy patients.

  2023cites this paper
• Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers

  2023cites this paper
• Long-Term Prevalence of Systolic Dysfunction in MYBPC3 Versus MYH7-Related Hypertrophic Cardiomyopathy

  2023cites this paper
• Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants

  2023cites this paper
• Cardiac Myosin Filaments are Maintained by Stochastic Protein Replacement

  2022cites this paper
• Transcriptional bursts and heterogeneity among cardiomyocytes in hypertrophic cardiomyopathy

  2022cites this paper
• Preponderant Myosin Super-Relaxed State In Skeletal Muscle From Endurance Athletes

  2022cites this paper
• Myosin as a novel key modulator of striated muscle metabolism.

  2022cites this paper
• Quantitative Proteomics and Network Analysis of Differentially Expressed Proteins in Proteomes of Icefish Muscle Mitochondria Compared with Closely Related Red-Blooded Species

  2022cites this paper
• Heterogeneous Distribution of Genetic Mutations in Myosin Binding Protein-C Paralogs

  2022cites this paper
• The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP‐C

  2022cites this paper
• Low expression of the K280N TNNT2 mutation is sufficient to increase basal myofilament activation in human hypertrophy cardiomyopathy

  2022cites this paper
• Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Review

  2022cites this paper
• Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy

  2022cites this paper
• Contraction pressure analysis using optical imaging in normal and MYBPC3-mutated hiPSC-derived cardiomyocytes grown on matrices with tunable stiffness

  2022cites this paper
• Phosphorylation-dependent interactions of myosin-binding protein C and troponin coordinate the myofilament response to protein kinase A

  2022cites this paper
• Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge

  2021cites this paper
• Toward an understanding of myofibrillar function in health and disease

  2021cites this paper
• FYCO1 Regulates Cardiomyocyte Autophagy and Prevents Heart Failure Due to Pressure Overload In Vivo

  2021cites this paper
• Ion Channel Impairment and Myofilament Ca2+ Sensitization: Two Parallel Mechanisms Underlying Arrhythmogenesis in Hypertrophic Cardiomyopathy

  2021influential citation
• Nanomechanical Phenotypes in Cardiac Myosin-Binding Protein C Mutants That Cause Hypertrophic Cardiomyopathy.

  2021cites this paper
• Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy

  2021cites this paper
• BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status

  2021cites this paper
• Cardiac myosin super relaxation (SRX): a perspective on fundamental biology, human disease and therapeutics

  2021cites this paper
• Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)

  2021cites this paper
• Cardiomyocyte Dysfunction in Inherited Cardiomyopathies

  2021cites this paper
• Contribution of Noncanonical Splice Variants to TTN Truncating Variant Cardiomyopathy

  2021cites this paper
• Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy

  2021cites this paper
• Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure

  2021cites this paper
• The emergency medical service has a crucial role to unravel the genetics of sudden cardiac arrest in young, out of hospital resuscitated patients.

  2021cites this paper
• Genetic Restrictive Cardiomyopathy: Causes and Consequences—An Integrative Approach

  2021cites this paper
• Assessment of the Contribution of a Thermodynamic and Mechanical Destabilization of Myosin-Binding Protein C Domain C2 to the Pathomechanism of Hypertrophic Cardiomyopathy-Causing Double Mutation MYBPC3Δ25bp/D389V

  2021cites this paper
• Cardiomyopathies in children: classification, diagnosis and treatment.

  2020cites this paper
• Genetic, clinical, molecular, and pathogenic aspects of the South Asian–specific polymorphic MYBPC3Δ25bp variant

  2020cites this paper
• Cardiomyopathies in children: classification, diagnosis and treatment.

  2020cites this paper
• Src/FAK complex phosphorylates cardiac myosin binding protein c (cMyBP-C) in vitro and in vivo

  2020cites this paper
• RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy

  2020cites this paper
• Heart Failure as a Consequence of Hypertrophic Cardiomyopathy

  2020cites this paper
• Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies

  2020cites this paper
• Protein Thermodynamic Destabilization in the Assessment of Pathogenicity of a Variant of Uncertain Significance in Cardiac Myosin Binding Protein C

  2020cites this paper
• Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue.

  2020cites this paper
• iPSCs for modeling of sarcomeric cardiomyopathies

  2020cites this paper
• Making waves: A proposed new role for myosin-binding protein C in regulating oscillatory contractions in vertebrate striated muscle

  2020cites this paper
• Benchmarking deep learning splice prediction tools using functional splice assays

  2020cites this paper
• Nanomechanical phenotypes in cMyBP-C mutants that cause hypertrophic cardiomyopathy

  2020cites this paper
• Targeting the population for gene therapy with MYBPC3.

  2020cites this paper
• Cardiomyopathy‐associated mutations in the RS domain affect nuclear localization of RBM20

  2020cites this paper
• The mechanisms of cardiac myopathies, a kinetics approach: Leading review

  2020cites this paper
• Gene Therapy for Inherited Arrhythmias.

  2020cites this paper
• Unraveling the Genotype‐Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity‐Related Cardiac Defects as a Major Disease Modifier

  2020cites this paper
• MYBPC3 Haplotype Linked to Hypertrophic Cardiomyopathy in Rhesus Macaques (Macaca mulatta).

  2020cites this paper
• Advanced Evolution of Pathogenesis Concepts in Cardiomyopathies

  2019cites this paper
• Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

  2019cites this paper
• CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation

  2019cites this paper
• Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies.

  2019cites this paper
• INDUCED PLURIPOTENT STEM CELLS FOR MODELLING ENERGETIC ALTERATIONS IN HYPERTROPHIC CARDIOMYOPATHY.

  2019cites this paper
• MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.

  2019cites this paper